The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2021Enhancing Treatment Efficacy by Eliminating L-dopa Metabolizing Gut Bacteria
Study Rationale: Levodopa (L-dopa) is the primary medication used to treat Parkinson’s disease (PD). For L-dopa to exert its effect, it must enter the brain and be converted to the chemical dopamine...
-
Research Grant, 2021Development of Selective PET Imaging Agents for Alpha-synuclein and Tau
Study Rationale: The ability to detect and monitor the accumulation of tau and alpha-synuclein aggregates in the brain is crucial to better understanding the pathophysiology of Progressive...
-
Outcome Measures, 2021Assessing Parkinson’s at Home: Contactless Monitoring of Sleep, Motor Symptom Progression and Medication Response
Study Rationale:
The ability to accurately monitor Parkinson’s disease (PD) progression and medication response at home can significantly benefit disease management and drug development. In the past... -
Improved Outcome Measures, 2021Development of PD Biomarkers Using Focused Ultrasound-based Noninvasive Biopsy
Study Rationale: There is an urgent need to develop non-invasive biomarkers that are able to diagnose and track the progression of Parkinson’s disease (PD). Focused ultrasound blood brain barrier...
-
Therapeutic Pipeline Program, 2021Harnessing the ADAR Protein to Repair the LRRK2 Mutation Causing Parkinson's Disease
Study Rationale:
The majority of cases of inherited Parkinson’s disease (PD) are caused by a single-letter change in the gene that encodes the LRRK2 protein. The mutation, which changes a G to an... -
Therapeutic Pipeline Program, 2021Evaluating the Safety, Tolerability and Potential Efficacy of SB-0107 for Treating Parkinson’s Disease and Levodopa-Induced Dyskinesia
Study Rationale:
Although levodopa is an effective treatment for Parkinson’s disease (PD), its ability to activate dopamine D1 receptors also leads to its most vexing side effect: dyskinesia. An...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.